<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048099</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 166</org_study_id>
    <nct_id>NCT01048099</nct_id>
  </id_info>
  <brief_title>Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the clinical significance of the PRO Onc assay and will assess the
      efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been
      identified as having HER2 overexpression/activation by the PRO Onc Assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two-part trial is designed to evaluate the clinical significance of the PRO Onc assay
      when used in patients with metastatic HER2-negative breast cancer. The first part of this
      study will determine the incidence of HER overexpression/activation, as determined by the PRO
      Onc assay, in patients previously judged to have HER2-negative breast cancer by FISH
      analysis. Blood specimens will be obtained from patients with HER2-negative breast cancer;
      CTCs will then be isolated and tested for HER2 overexpression/activation using the PRO Onc
      Assay. When clinically indicated, fine needle aspiration biopsy will also be obtained and
      submitted for the PRO Onc Assay. If the incidence of HER2 overexpression/activation, as
      determined by the PRO Onc Assay, is &gt;10%, the study will proceed to Part 2. Part 2 of this
      study will assess the efficacy of HER2-targeted therapy in a group of patients with
      HER2-negative breast cancer who are identified as having HER2 overexpression/activation by
      the PRO Onc Assay. Patients will be treated with either trastuzumab or pertuzumab. Patients
      who progress during the first 8 weeks will have HER2-targeted treatment discontinued and will
      be removed from study. After 8 weeks, patients who have stable disease will be allowed to add
      chemotherapy to HER2-targeted therapy. Patients who have an objective response to
      single-agent, HER2-targeted therapy after 8 weeks will continue single-agent therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)</measure>
    <time_frame>18 months</time_frame>
    <description>The percentage of HER2-negative metastatic breast cancer (MBC) patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Objective Response Rate of Trastuzumab Therapy</measure>
    <time_frame>18 months</time_frame>
    <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression as identified by the PRO Onc Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Objective Response Rate of Pertuzumab Therapy</measure>
    <time_frame>18 months</time_frame>
    <description>The percentage of patients with HER2 activation (no overexpression) as identified by the PRO Onc Assay who experience an objective benefit from treatment, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: The Incidence of HER2 Overexpression/Activation as Measured by the PRO Onc Assay</measure>
    <time_frame>12 months</time_frame>
    <description>Includes patients with HER2-negative metastatic breast cancer (MBC) as determined by FISH testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: The Incidence of Isolation of Circulating Tumor Cells (CTCs) From Blood Specimens</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of HER2-negative MBC patients (identified by FISH testing) having CTCs present in blood specimens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PRO Onc Assay and Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PRO Onc Assay and Treatment</intervention_name>
    <description>Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.</description>
    <arm_group_label>PRO Onc Assay and Treatment</arm_group_label>
    <other_name>blood draw</other_name>
    <other_name>fine needle aspiration</other_name>
    <other_name>circulating tumor cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks</description>
    <arm_group_label>PRO Onc Assay and Treatment</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks</description>
    <arm_group_label>PRO Onc Assay and Treatment</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part I

          1. Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may
             have been performed on the primary tumor, or subsequently on a biopsy of a metastatic
             lesion.)

          2. Patients should be currently receiving chemotherapy, or scheduled to start
             chemotherapy (second-line or subsequent), for HER2-negative metastatic breast cancer.

          3. To begin protocol treatment, patients must have progressed after at least 1 previous
             chemotherapy regimen for metastatic breast cancer.

          4. Patients who are ER/PR positive or negative are eligible. ER/PR positive patients
             should be refractory to hormonal therapy, or not good candidates for hormonal therapy
             due to clinical features.

          5. ECOG performance status of 0, 1 or 2.

          6. Adequate recovery from recent surgery; ≥ 1 week must have elapsed from the time of a
             minor surgery; ≥ 4 weeks must have elapsed from the time of a major surgery.

          7. Patients must have measurable disease per RECIST criteria.

          8. Laboratory values as follows: Absolute neutrophil count (ANC) ≥1500/μL Hemoglobin
             (Hgb) ≥10 g/dL Platelets ≥100,000/L AST or ALT and alkaline phosphatase (ALP) must be
             &lt;2.5 x ULN, or &lt;5 x ULN in patients with liver metastases. Total bilirubin &lt;1.5 x the
             institutional ULN Serum creatinine &lt;1.5 x institutional ULN or calculated creatinine
             clearance ≥45 mL/min

             Patients from Part 1 who have HER2 overexpression/activation identified by the PRO Onc
             Assay may enter the treatment portion of Part 2, if they meet all Part 2 eligibility
             criteria.

          9. Life expectancy of ≥ 12 weeks.

         10. Patient must be accessible for treatment and follow-up.

         11. Patients must be able to understand the investigational nature of this study and give
             written informed consent prior to study entry.

        Part II

          1. Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may
             have been performed on the primary tumor, or subsequently on a biopsy of a metastatic
             lesion.)

          2. Patients should be currently receiving chemotherapy, or scheduled to start
             chemotherapy, for HER2-negative metastatic breast cancer.

          3. Patients who are ER/PR positive or negative are eligible. ER/PR positive patients
             should be refractory to hormonal therapy, or not good candidates for hormonal therapy
             due to clinical features.

          4. ECOG performance status of 0, 1 or 2.

          5. Adequate recovery from recent surgery; ≥ 1 week must have elapsed from the time of a
             minor surgery; ≥ 4 weeks must have elapsed from the time of a major surgery.

          6. Patients must have measurable disease per RECIST criteria.

          7. Laboratory values as follows:

               -  Absolute neutrophil count (ANC) ≥1500/μL

               -  Hemoglobin (Hgb) ≥10 g/dL

               -  Platelets ≥100,000/uL

               -  AST or ALT and alkaline phosphatase (ALP) must be &lt;2.5 x ULN, or &lt;5 x ULN in
                  patients with liver metastases.

               -  Total bilirubin &lt;1.5 x the institutional ULN

               -  Serum creatinine &lt;1.5 x institutional ULN or calculated creatinine clearance ≥45
                  mL/min

          8. Life expectancy of ≥ 12 weeks.

          9. Patient must be accessible for treatment and follow-up.

         10. Patients must be able to understand the investigational nature of this study and give
             written informed consent prior to study entry.

         11. Patients who are eligible for HER2-targeted treatment will begin this treatment at the
             first time a treatment change is necessary (i.e. at the next progression of metastatic
             breast cancer). This may occur immediately after PRO Onc assay results are received,
             or may be several months later, for patients responding well to their current
             chemotherapy.

         12. Patients must continue to meet all inclusion and exclusion criteria for the Part 2
             screening population at the time they are ready to start HER2-targeted treatment.

         13. Ejection fraction ≥ 50%, as measured by echocardiogram (ECHO) or MUGA.

        Exclusion Criteria:

        Part I:

          1. Patients currently responding to hormonal therapy.

          2. Previous treatment with any HER2-targeted agent.

          3. Patients with meningeal metastases.

          4. Patients who are not considered likely candidates for subsequent therapy after next
             progression of metastatic breast cancer.

          5. Women who are pregnant or lactating.

          6. Patients with New York Heart Association class II or greater congestive heart failure.

          7. Any of the following ≤6 months prior to starting study treatment:

               -  myocardial infarction;

               -  severe unstable angina;

               -  ongoing cardiac dysrhythmia

          8. Concurrent severe, intercurrent illness including, but not limited to, ongoing or
             active infection, or psychiatric illness/social situations that would limit safety and
             compliance with study requirements.

          9. Mental condition that would prevent patient comprehension of the nature of, and risk
             associated with, the study.

         10. Use of any non-approved or investigational agent ≤ 30 days of administration of the
             first dose of study drug. Patients may not receive any other investigational or
             anti-cancer treatments while participating in this study.

        Part II

          1. Patients currently responding to hormonal therapy.

          2. Previous treatment with any HER2-targeted agent.

          3. Patients with meningeal metastases.

          4. Patients with active brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if there is no evidence of central nervous system
             (CNS) disease progression, and at least 4 weeks have elapsed since treatment. Ideally,
             patients should not still require use of seizure medication or steroids.

          5. Patients who are not considered likely candidates for subsequent therapy after next
             progression of metastatic breast cancer.

          6. Women who are pregnant or lactating.

          7. Patients with New York Heart Association class II or greater congestive heart failure.

          8. Any of the following ≤6 months prior to starting study treatment:

               -  myocardial infarction;

               -  severe unstable angina;

               -  ongoing cardiac dysrhythmia.

          9. Concurrent severe, intercurrent illness including, but not limited to, ongoing or
             active infection, or psychiatric illness/social situations that would limit safety and
             compliance with study requirements.

         10. Mental condition that would prevent patient comprehension of the nature of, and risk
             associated with, the study.

         11. Use of any non-approved or investigational agent ≤ 30 days of administration of the
             first dose of study drug. Patients may not receive any other investigational or
             anti-cancer treatments while participating in this study.

         12. Past or current history of neoplasm other than the entry diagnosis with the exception
             of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other
             cancers cured by local therapy alone and a DFS ≥5 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Hainsworth, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>October 8, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>PRO Onc Assay</keyword>
  <keyword>FISH Testing</keyword>
  <keyword>HER Negative</keyword>
  <keyword>HER Overexpression</keyword>
  <keyword>HER Activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pts with HER2-negative, metastatic breast cancer were enrolled. Blood was collected to perform the PRO Onc Circulating Tumor Cell (CTC). Pts without CTCs present were taken off-study. Following the assay, pts without detected HER2 overexpression/activation were taken off-study. Of the remaining pts, those FISH-positive for HER2 came off-study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Patients Enrolled and Blood Collected</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="283">Patients enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226">Patients with circulating tumor cells (CTCs)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients without circulating tumor cells</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Patients Evaluated by PRO Onc Assay</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226">Patients with CTCs who were evaluated by PRO Onc Assay</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">Patients evaluated by PRO Onc Assay with HER2 overexpression/activation detected</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients with no HER2 abnormality</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pts w/ HER2 Overexpression/Activation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24">Patients with detected HER2 activation and/or overexpression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">Patients who proceeded to treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Per Protocol</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients continued treatment until disease progression or coming off-study for any other reason</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Excludes patients with no circulating tumor cells for the PRO Onc Assay</population>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated</title>
          <description>Patients who received study treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="47" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: The Incidence of HER2 Overexpression/Activation as Measured by the PRO Onc Assay</title>
        <description>Includes patients with HER2-negative metastatic breast cancer (MBC) as determined by FISH testing.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Evaluated by PRO Onc Assay</title>
          </group>
        </group_list>
        <measure>
          <title>Part 1: The Incidence of HER2 Overexpression/Activation as Measured by the PRO Onc Assay</title>
          <description>Includes patients with HER2-negative metastatic breast cancer (MBC) as determined by FISH testing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HER2 overexpressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2 activated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2 overexpressed and activated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No HER2 overexpression/activation detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)</title>
        <description>The percentage of HER2-negative metastatic breast cancer (MBC) patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated</title>
            <description>Patients who received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)</title>
          <description>The percentage of HER2-negative metastatic breast cancer (MBC) patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: The Incidence of Isolation of Circulating Tumor Cells (CTCs) From Blood Specimens</title>
        <description>Percentage of HER2-negative MBC patients (identified by FISH testing) having CTCs present in blood specimens.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all patients with blood drawn and analyzed for CTCs</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Part I: The Incidence of Isolation of Circulating Tumor Cells (CTCs) From Blood Specimens</title>
          <description>Percentage of HER2-negative MBC patients (identified by FISH testing) having CTCs present in blood specimens.</description>
          <population>Includes all patients with blood drawn and analyzed for CTCs</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Objective Response Rate of Trastuzumab Therapy</title>
        <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression as identified by the PRO Onc Assay.</description>
        <time_frame>18 months</time_frame>
        <population>Includes patients with HER2 overexpression detected by the PRO Onc Assay</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated</title>
            <description>Patients who received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Objective Response Rate of Trastuzumab Therapy</title>
          <description>The percentage of patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Includes patients with HER2 overexpression as identified by the PRO Onc Assay.</description>
          <population>Includes patients with HER2 overexpression detected by the PRO Onc Assay</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Objective Response Rate of Pertuzumab Therapy</title>
        <description>The percentage of patients with HER2 activation (no overexpression) as identified by the PRO Onc Assay who experience an objective benefit from treatment, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>18 months</time_frame>
        <population>Includes patients with only HER2 activation (no overexpression) as detected by the PRO Onc Assay</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated</title>
            <description>Patients who received study treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Objective Response Rate of Pertuzumab Therapy</title>
          <description>The percentage of patients with HER2 activation (no overexpression) as identified by the PRO Onc Assay who experience an objective benefit from treatment, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Includes patients with only HER2 activation (no overexpression) as detected by the PRO Onc Assay</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Treated Patients</title>
          <description>Includes all patients with HER2 overexpression/activation (as identified by the PRO Onc Assay) who received study treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, thoracic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

